Tacrolimus-Associated Tremor in Renal Transplant Patients: Potential Impact of the Galenic Formulation.

ABSTRACT: Background/Objectives: Tacrolimus is the most used immunosuppressive agent in solid organ transplantation due to its efficacy in preventing acute rejection, but it has a narrow therapeutic range, and overexposure often leads to toxicities, including neurological side effects like tremors. Tremor affects up to 54% of renal transplant patients under tacrolimus. Extended-release tacrolimus (LCPT) has demonstrated efficacy in reducing tremor severity, as evidenced by studies employing quality of life (QoL) questionnaires, the Fahn-Tolosa-Marin (FTM) scale, and Accelerometer devices. The objectives of this study were to evaluate the benefits of the conversion to LCPT formulation in kidney transplant recipients experiencing tremors on prolonged-release tacrolimus (PR-TAC) treatment and to

SUBMITTER: Rovira J 

PROVIDER: S-EPMC12566630 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature